
Antonio Manzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7057985/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium. PLoS Medicine, 2009, 6, e1.	8.4	443
2	Systematic microanatomical analysis of CXCL13 and CCL21in situ production and progressive lymphoid organization in rheumatoid synovitis. European Journal of Immunology, 2005, 35, 1347-1359.	2.9	232
3	Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in SjA¶gren's syndrome. Arthritis and Rheumatism, 2005, 52, 1773-1784.	6.7	226
4	Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology, 2017, 13, 463-475.	8.0	175
5	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Research and Therapy, 2013, 15, R172.	3.5	143
6	Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunological Reviews, 2010, 233, 267-285.	6.0	127
7	Mature antigenâ€experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis and Rheumatism, 2008, 58, 3377-3387.	6.7	124
8	B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers. BioMed Research International, 2014, 2014, 1-14.	1.9	121
9	Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis and Rheumatism, 2002, 46, 824-836.	6.7	112
10	Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiology of Disease, 2014, 62, 218-232.	4.4	110
11	CCL21 Expression Pattern of Human Secondary Lymphoid Organ Stroma Is Conserved in Inflammatory Lesions with Lymphoid Neogenesis. American Journal of Pathology, 2007, 171, 1549-1562.	3.8	94
12	Involvement of subchondral bone marrow in rheumatoid arthritis: Lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis and Rheumatism, 2005, 52, 3448-3459.	6.7	93
13	Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 226.	3.5	87
14	Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology, 2015, 54, 2264-2272.	1.9	83
15	Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunology Letters, 2012, 145, 62-67.	2.5	79
16	The Clinical Value of Autoantibodies in Rheumatoid Arthritis. Frontiers in Medicine, 2018, 5, 339.	2.6	64
17	Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Research and Therapy, 2007, 9, R101.	3.5	63
18	High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology, 2014, 53, 1886-1895.	1.9	63

ANTONIO MANZO

#	Article	IF	CITATIONS
19	IL-6 Amplifies TLR Mediated Cytokine and Chemokine Production: Implications for the Pathogenesis of Rheumatic Inflammatory Diseases. PLoS ONE, 2014, 9, e107886.	2.5	58
20	Stromal Cell-Derived Factor 1 (CXCL12) Induces Human Cell Migration into Human Lymph Nodes Transplanted into SCID Mice. Journal of Immunology, 2002, 168, 4308-4317.	0.8	48
21	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Research and Therapy, 2012, 14, R34.	3.5	47
22	Multilevel examination of minor salivary gland biopsy for Sjogren's syndrome significantly improves diagnostic performance of AECG classification criteria. Arthritis Research, 2005, 7, R343.	2.0	46
23	Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. Arthritis Research and Therapy, 2012, 14, 229.	3.5	43
24	Current concepts and new developments in the treatment of psoriatic arthritis. British Journal of Rheumatology, 2003, 42, 1138-1148.	2.3	41
25	Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 2118.	4.8	40
26	Human singleâ€chain variable fragment that specifically targets arthritic cartilage. Arthritis and Rheumatism, 2010, 62, 1007-1016.	6.7	39
27	Use of Ultrasoundâ€Guided Small Joint Biopsy to Evaluate the Histopathologic Response to Rheumatoid Arthritis Therapy: Recommendations for Application to Clinical Trials. Arthritis and Rheumatology, 2015, 67, 2601-2610.	5.6	39
28	Synovial Tissue Heterogeneity and Peripheral Blood Biomarkers. Current Rheumatology Reports, 2011, 13, 440-448.	4.7	38
29	Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography. Rheumatology, 2011, 50, 1395-1400.	1.9	36
30	Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency. Arthritis Research and Therapy, 2014, 16, R151.	3.5	35
31	A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis. Arthritis and Rheumatology, 2018, 70, 702-710.	5.6	32
32	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter — Determining Validation Requirements. Journal of Rheumatology, 2016, 43, 208-213.	2.0	30
33	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. Arthritis Research and Therapy, 2018, 20, 265.	3.5	29
34	Lymphoid tissue reactions in rheumatoid arthritis. Autoimmunity Reviews, 2007, 7, 30-34.	5.8	28
35	The Draining Lymph Node in Rheumatoid Arthritis: Current Concepts and Research Perspectives. BioMed Research International, 2015, 2015, 1-10.	1.9	27
36	Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis. Annals of the Rheumatic Diseases, 2022, 81, 214-224.	0.9	26

Antonio Manzo

#	Article	IF	CITATIONS
37	Assessment of synovitis to predict bone erosions in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 235-244.	2.7	25
38	Circulating Interferonâ€Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 440-445.	3.4	24
39	Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis. Journal of Autoimmunity, 2019, 99, 81-97.	6.5	22
40	B cell autoimmunity and bone damage in rheumatoid arthritis. Reumatismo, 2016, 68, 117-125.	0.9	20
41	ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis. RMD Open, 2017, 3, e000441.	3.8	19
42	Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 625-626.	0.9	18
43	The synovial membrane as a prognostic tool in rheumatoid arthritis. Autoimmunity Reviews, 2007, 6, 248-252.	5.8	16
44	The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis. International Journal of Molecular Sciences, 2021, 22, 12386.	4.1	15
45	Established rheumatoid arthritis. The pathogenic aspects. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101478.	3.3	14
46	Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. Arthritis Research and Therapy, 2016, 18, 242.	3.5	13
47	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 1640-1646.	0.9	12
48	Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110118.	2.7	9
49	Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target. Frontiers in Immunology, 2021, 12, 701922.	4.8	8
50	Histopathology of the synovial tissue: perspectives for biomarker development in chronic inflammatory arthritides. Reumatismo, 2018, 70, 121-132.	0.9	7
51	Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?. Frontiers in Medicine, 2018, 5, 140.	2.6	7
52	Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 1206-1213.	0.9	6
53	Clinical Applications of Synovial Biopsy. Frontiers in Medicine, 2019, 6, 102.	2.6	5
54	Insights Into the Concept of Rheumatoid Arthritis Flare. Frontiers in Medicine, 2022, 9, 852220.	2.6	4

Antonio Manzo

#	Article	IF	CITATIONS
55	B cell distribution and activation-induced cytidine deaminase expression in rheumatoid synovitis: clinical and bio-molecular correlates. Annals of the Rheumatic Diseases, 2011, 70, A55-A55.	0.9	3
56	THU0058â€B CELL SYNOVITIS AND CLINICAL PHENOTYPES IN RHEUMATOID ARTHRITIS AT DIFFERENT DISEASE STAGES. , 2019, , .		2
57	Chemokines in arthritis: key molecules in pathogenesis and potential therapeutic targets. Future Rheumatology, 2006, 1, 53-65.	0.2	2
58	Targeting therapeutics to arthritic joints by antibody specific to post-translationally modified collagen type II. Annals of the Rheumatic Diseases, 2012, 71, A7.2-A7.	0.9	1
59	THU0234â€Short-Term Clinical Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in Dmards-Induced SDAI Remission under Drug-Free Conditions. Annals of the Rheumatic Diseases, 2014, 73, 263.1-263.	0.9	1
60	SAT0087â€Serum Levels of CXCL13 Refine The Predictive Ability of Autoantibodies To Identify Unstable Remission in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 696.3-696.	0.9	1
61	A5.14â€Serum CXCL13 is a non-invasive synovitis marker holding non-redundant information compared with acute phase reactants and autoantibodies in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A46.3-A47.	0.9	1
62	THU0099â€The 2010 classification criteria and a more aggressive treatment strategy improve clinical outcomes in seropositive but not seronegative rheumatoid arthritis. , 2017, , .		1
63	SAT0060â€Response to conventional synthetic dmards differs depending on rheumatoid factor levels in anti-citrullinated positive patients with early rheumatoid arthritis. , 2017, , .		1
64	THU0546â€Serum CXCL13 as A Biomarker of Disease Activity and Severity in IN Rheumatoid Arthritis. Comparison with Acute Phase Reactants and the Autoantibody Profile. Annals of the Rheumatic Diseases, 2014, 73, 371.2-371.	0.9	1
65	Lymphoid neogenesis in chronic inflammation. Arthritis Research, 2003, 5, 116.	2.0	0
66	Title is missing!. Arthritis Research, 2005, 7, P139.	2.0	0
67	Multicentric Study Of Hospitalized Patients Affected By H1N1 Influenza In Mar Del Plata, Argentina, During The June To August 2009 Period. , 2010, , .		0
68	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2012, 71, A12.3-A13.	0.9	0
69	SAT0114â€Synovial B cell infiltration in relationship to diagnosis and outcome in early arthritis according to the 2010 ACR/EULAR classification criteria. Annals of the Rheumatic Diseases, 2013, 71, 508.3-509.	0.9	0
70	A1.13â€Ultrasound-guided assessement of axillary lymph nodes in rheumatoid arthritis: cross-sectional and prospective clinico-pathologic significance. Annals of the Rheumatic Diseases, 2014, 73, A6.1-A6.	0.9	0
71	FRI0344â€IL-9 and CD4+II9+ T Lymphocytes Are over Expressed in the Synovium of Patients with Rheumatoid Arthritis, Elicited in Vitro by Citrullinated Peptide Incubation and the Abrogation of Pu.1 in Mice Interfere with the Collagen Induced Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 511.3-512.	0.9	0
72	FRI0067â€Anti-Citrullinated Protein Antibodies and Generalised Bone Loss in Patients with Early Rheumatoid Arthritis: A Causal Relationship?. Annals of the Rheumatic Diseases, 2014, 73, 405.3-406.	0.9	0

ANTONIO MANZO

#	Article	IF	CITATIONS
73	A8.29†Outcome and predictors of relapse in early rheumatoid arthritis patients achieving DMARDs-induced stable remission during drug-free follow-up. Annals of the Rheumatic Diseases, 2015, 74, A93.2-A93.	0.9	0
74	THU0120â€Prognostic Significance of Residual Autoimmune/Inflammatory Activity for Disease Relapse Upon Dmard Suspension in Patients with Early Rheumatoid Arthritis in Sustained Remission After DAS-Driven Therapy. Annals of the Rheumatic Diseases, 2015, 74, 237.3-237.	0.9	0
75	A5.13â€Power-doppler ultrasound assessment of the joint-draining lymph node complex in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A46.2-A46.	0.9	0
76	SAT0540â€Power Doppler Ultrasound Imaging of The Joint-Draining Lymph Node Complex in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 864.3-865.	0.9	0
77	Compartmental modeling of F-DOPA PET images from Parkinson's patients. AlP Conference Proceedings, 2016, , .	0.4	0
78	SAT0053â€The incident immunological status predicts drug-free disease flare in rheumatoid arthritis patients achieving stringent clinical and ultrasonographic control of the peripheral inflammatory process. , 2017, , .		0
79	THU0667â€A qualitative and quantitative comparison of synovial biopsy techniques during clinical trials of inflammatory arthritis. , 2017, , .		Ο
80	FRI0145â€FACTORS ASSOCIATED WITH NEAR REMISSION DIFFER BETWEEN AUTOANTIBODY-POSITIVE AND -NEGATIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. , 2019, , .		0
81	THU0164â€THE DAS28 BASED ON THE ERYTHROCYTE SEDIMENTATION RATE MAY OVERESTIMATE DISEASE ACTIVITY IN EARLY, TREATMENT-NAÃVE PATIENTS WITH RHEUMATOID ARTHRITIS WITH HIGH LEVELS OF RHEUMATOID FACTOR. , 2019, , .		0
82	THU0079â€AUTOANTIBODY-NEGATIVE PATIENTS, THE CUT-OFF OF SIX POINTS ACCORDING TO THE 2010 ACR/EULAR CRITERIA FOR RHEUMATOID ARTHRITIS MAY MISS A POPULATION OF SEVERE, PERSISTENT POLYARTHRITIS. , 2019, , .		0
83	FRI0035â€Disease remission is more common but less stringent in anti-citrullinated protein antibody-positive patients with early rheumatoid arthritis treated with conventional synthetic disease modifying drugs. , 2018, , .		0
84	AB0203â€Clinical phenotype and ultrasound characteristics of rheumatoid arthritis flare after discontinuation of conventional synthetic dmards. , 2018, , .		0
85	THU0111â€Frequency and predictors of sustained remission in patients with early rheumatoid arthritis treated with conventional synthetic disease modifying drugs. , 2018, , .		0
86	No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission. Clinical Rheumatology, 0, , .	2.2	0